URGENT: This Altcoin Opportunity Won’t Wait – Act Now

It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.

Stephen Fry Biography and Net Worth

SVP of Eli Lilly and Company

Steve Fry is senior vice president, human resources and diversity, for Eli Lilly and Company.

Since joining Lilly in 1987 as a scientific systems analyst in Lilly Research Laboratories, Steve has held a range of roles in information technology and human resources. Following a series of managerial assignments, Steve served as human resources director for Lilly’s U.K. affiliate and then as executive director of human resources for the U.S. affiliate. In 2004 he was named managing director of the Australian affiliate, returning to the U.S. in 2007 to provide HR leadership for the global sales and marketing organization before accepting the role of vice president supporting the Lilly Bio-Medicines and Emerging Markets business units. He assumed his current role in 2011.

Steve earned his bachelor’s degree in information systems from the University of Indianapolis.

Steve serves on the board of trustees at the University of Indianapolis and the board of Ascend Indiana. He previously served on the governance board for Make-A-Wish in Ohio, Kentucky, and Indiana from 2012-2019.

What is Stephen F. Fry's net worth?: The estimated net worth of Stephen F. Fry is at least $84.56 million as of March 30th, 2020. Mr. Fry owns 110,572 shares of Eli Lilly and Company stock worth more than $84,555,514 as of December 18th. This net worth estimate does not reflect any other investments that Mr. Fry may own. Learn More about Stephen F. Fry's net worth.
How do I contact Stephen F. Fry?: The corporate mailing address for Mr. Fry and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Stephen F. Fry's contact information.
Has Stephen F. Fry been buying or selling shares of Eli Lilly and Company?: Stephen F. Fry has not been actively trading shares of Eli Lilly and Company in the last ninety days. Most recently, Stephen F. Fry sold 14,657 shares of the business's stock in a transaction on Monday, March 30th. The shares were sold at an average price of $134.30, for a transaction totalling $1,968,435.10. Following the completion of the sale, the senior vice president now directly owns 110,572 shares of the company's stock, valued at $14,849,819.60. Learn More on Stephen F. Fry's trading history.
Who are Eli Lilly and Company's active insiders?: Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (EVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.
Are insiders buying or selling shares of Eli Lilly and Company?: In the last year, insiders at the sold shares 26 times. They sold a total of 1,410,659 shares worth more than $1,192,819,015.29. The most recent insider tranaction occured on November, 8th when CAO Donald A Zakrowski sold 900 shares worth more than $723,042.00. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.
Information on this page was last updated on 11/8/2024.

Stephen F. Fry Insider Trading History at Eli Lilly and Company

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/30/2020	Sell	14,657	$134.30	$1,968,435.10	110,572
9/5/2019	Sell	9,452	$115.00	$1,086,980.00	100,211
3/12/2019	Sell	14,847	$123.16	$1,828,556.52	109,663
2/5/2016	Sell	15,230	$78.87	$1,201,190.10	59,690
3/9/2015	Sell	4,000	$69.27	$277,080.00

Stephen F. Fry Buying and Selling Activity at Eli Lilly and Company

Eli Lilly and Company Company Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $764.71

$762.50

$779.00

50 Day Range

MA: $828.39

$727.57

$932.06

2 Week Range

Now: $764.71

$567.02

$972.53

Volume

3,303,963 shs

Average Volume

3,209,608 shs

Market Capitalization

$725.95 billion

P/E Ratio

82.67

Dividend Yield

0.66%

Beta

0.41

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad